You are here: Home » International » News » Companies
Business Standard

Celgene to acquire Impact Biomedicines for up to $7 billion

Celgene is interested in Impact Biomedicines' fedratinib that has shown promise as a potential treatment for a type of blood cancer

Reuters  |  New York 

US biotech pharmaceutical firm Celgene said on Sunday that it had agreed to acquire Impact Biomedicines for as much as $7 billion, subject to certain milestones associated with regulatory hurdles and sales performance. Celgene is interested in Impact Biomedicines’ fedratinib, a kinase inhibitor that has shown promise as a potential treatment for a type of blood cancer called myelofibrosis, according to a statement put out jointly by both companies. “Myelofibrosis is a disease with high unmet medical need as the number of patients who are ineligible for or become ...

This article is no longer available in our repository.

There could be multiple reasons for this.

First Published: Tue, January 09 2018. 02:22 IST
RECOMMENDED FOR YOU